🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Netherlands
Clinical trial register · European Union · CTIS

Clinical Trials in Netherlands

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
524 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
Cosmos Trial: Cerebroprotection Of AST-004 in Mild Complicated Traumatic Brain Injuries
2026-525554-11-00Traumatic brain injury
Astrocyte Pharmaceuticals Inc.
Nervous System Diseases
Netherlands
04/06/2026
Phase I/II
A Phase 1b/2 Study to Evaluate NB-4746 in Participants with Amyotrophic Lateral Sclerosis.
2025-523939-18-00Amyotrofic Lateral Sclerosis (ALS)
Nura Bio Inc.
Nervous System Diseases
Poland, Netherlands, Italy, Spain
03/06/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
2025-523911-13-00Narcolepsy Type 1
Alkermes Inc.
Nervous System Diseases
Italy, France, Netherlands, Spain, Belgium, Austria, Czechia, Finland, Germany, Sweden, Norway, Poland
02/06/2026
Phase III
A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS FACTOR VIII PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS
2025-522434-32-00Hemophilia A Without Inhibitors
F. Hoffmann-La Roche AG
Hemic and Lymphatic Diseases
France, Austria, Poland, Netherlands, Spain, Denmark, Italy, Germany, Hungary
01/06/2026
Phase I
GRAIN, Prospective Pilot Study
2025-524470-41-00Esophageal dysplasia, Barrett's esophagus, Esophageal adeno…
Universitair Medisch Centrum Groningen
Neoplasms
Netherlands
01/06/2026
Phase III
Post-INFECT: Investigating Neuroinflammation and its eFEcts in post-COVID syndrome: an imaging sTudy
2025-522349-23-00post-COVID syndrome
Amsterdam UMC Stichting
Virus Diseases
Netherlands
01/06/2026
Phase III
A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A
2025-522435-33-00Hemophilia A
F. Hoffmann-La Roche AG
Hemic and Lymphatic Diseases
Hungary, Spain, Ireland, Poland, Austria, Germany, Denmark, Belgium, Netherlands, Italy, France
01/06/2026
Phase I/II
A Phase 1b/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants with Late-Onset Pompe Disease
2025-524082-25-00Late-Onset Pompe Disease
Denali Therapeutics Inc.
Musculoskeletal Diseases
Germany, Netherlands
01/06/2026
Phase II
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
2024-516570-30-00Relapsed/refractory T-cell Acute Lymphoblastic Leukemia
Centre Hospitalier De Versailles
Hemic and Lymphatic Diseases
Germany, France, Czechia, Netherlands, Spain
29/05/2026
Phase I/II
C6461006 - An Interventional Phase 1b/2, Open-Label Study to Investigate the Safety, Antitumor Activity, and Pharmacokinetics of PF-08634404 Monotherapy or in Combination With Enfortumab Vedotin in Adult Participants With Locally Advanced or Metastatic Urothelial Cancer.
2025-523523-21-00Locally Advanced or Metastatic Urothelial Cancer
Pfizer Inc.
Neoplasms
Netherlands, Spain
29/05/2026
Phase III
A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive
2025-523555-66-00Myelofibrosis
Novartis Pharma AG
Neoplasms
Belgium, Germany, Austria, Poland, Spain, Italy, Netherlands, Czechia, France
29/05/2026
Phase II
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX‑828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis
2025-523400-72-00Cystic fibrosis
Vertex Pharmaceuticals Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Sweden, Germany, Italy, Belgium, Czechia, Ireland, Portugal, Netherlands, France, Denmark
29/05/2026
Phase III
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease
2025-521590-13-00Moderately to Severely Active Crohn’s Disease
Janssen Cilag International
Immune System Diseases
Slovakia, Germany, Denmark, France, Spain, Italy, Netherlands, Belgium, Poland, Sweden, Austria, Czechia, Hungary
27/05/2026
Phase III
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy
2025-522949-22-00Duchenne muscular dystrophy
Solid Biosciences Inc.
Musculoskeletal Diseases
Spain, Netherlands, France, Italy, Belgium, Germany
26/05/2026
Phase I/II
LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
2025-522339-32-00Neoplasm malignant
Merck Sharp & Dohme LLC
Neoplasms
France, Spain, Sweden, Germany, Italy, Belgium, Denmark, Czechia, Hungary, Netherlands, Slovakia
26/05/2026
Phase II
Repurposed Drug Evaluation for Biological Aging, Pain, and Inflammation Reduction in Osteoarthritis
2025-524885-12-00Osteoarthritis
Radboud universitair medisch centrum Stichting
Musculoskeletal Diseases
Netherlands
26/05/2026
Phase I
Thorough QT/QTc study with GLPG3667, placebo, and active comparator in healthy subjects
2026-525788-42-00Healthy volunteers
Galapagos
Not possible to specify
Netherlands
22/05/2026
Phase I
150 mg CIT-013 phase 1 trial
2026-526153-34-00Immune mediated inflammatory diseases
Citryll B.V.
Immune System Diseases
Netherlands
22/05/2026
Phase III
ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy
2025-523576-23-00Unresectable Stage III non-small cell lung cancer without p…
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
France, Ireland, Germany, Greece, Bulgaria, Spain, Netherlands, Italy, Sweden, Romania, Hungary, Belgium, Austria, Poland
22/05/2026
Phase II
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).
2025-525013-23-00Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)
Eikon Therapeutics Inc.
Neoplasms
Germany, Spain, Netherlands, Romania, Greece, Italy, Austria, Belgium, Bulgaria, France, Hungary, Poland
21/05/2026
Phase I
Clinical trial to evaluate the safety, tolerability and effectiveness of a medicinal nasal insert in the treatment of chronic hay fever.- Inspicare
2026-525200-99-00Chronic allergic rhinitis
Dianosic
Respiratory Tract Diseases
Netherlands
21/05/2026
Phase I
SAR447971 first-in-human study
2026-525333-22-00Hidradenitis
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Netherlands
20/05/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
2025-523087-20-00Duchenne muscular dystrophy
Avidity Biosciences Inc.
Musculoskeletal Diseases
Italy, Germany, France, Spain, Belgium, Poland, Netherlands
20/05/2026
Phase II
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
2025-524005-32-00Rheumatoid arthritis
Elevara Medicines Limited
Immune System Diseases
Czechia, Bulgaria, Hungary, Netherlands, Poland, Spain
19/05/2026
Phase III
A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)
2025-521632-12-00Patients on Factor Xa inhibitor treatment needing an urgent…
VarmX B.V.
Hemic and Lymphatic Diseases
Belgium, Germany, Italy, France, Czechia, Bulgaria, Hungary, Spain, Netherlands, Poland, Austria, Estonia, Romania, Portugal, Lithuania
19/05/2026
Rows per page Showing 126–150 of 524
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe/country/netherlands

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.